Glycolate Oxidase Inhibitor
-
Lumasiran
0 ImagesCat. No.: HY-132588CAS No.: 1834610-13-7Synonyms: ALN-G01Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
-
Lumasiran sodium
0 ImagesLumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
-
Lumasiran sodium scrambled negative control
0 ImagesCat. No.: HY-132613ALumasiran sodium scrambled negative control is the sequence scrambled negative control of Lumasiran sodium.
